Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

To answer questions on what the company is current

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30067
Posted On: 08/24/2014 4:57:01 PM
Avatar
Posted By: Mauibound
To answer questions on what the company is currently doing, what they intend to do, what they are projecting, what they expect and what announcements they have coming up...

Just go to the source....

The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter

We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory....

We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study , and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro)

We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID)

We have significant announcements forthcoming in the weeks and months ahead for MANF including the complete data sets regarding ophthalmological toxicology studies, Retinitis Pigmentosa functional data assessments and additional efficacy data sets, initial data from our research collaboration with the University of Washington on Wolfram’s Syndrome retinal degeneration, intracranial delivery data for our Parkinson’s program collaboration with Renishaw, additional data from undisclosed activities for MANF, the initiation of GMP manufacturing in preparation for first-in-man studies, the filing of Orphan Drug Designation for MANF in Retinitis Pigmentosa, and potential business development activity around the MANF Program.

http://www.thechairmansblog.com/amarantus-bio...1bJeT.dpuf

Business Update Call
September 2, 2014 at 4:15 pm ET


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us